A 49-year-old man was evaluated because of relapsed acute myeloid leukemia that occurred 14 months after the initial diagnosis and treatment. Molecular genetic profiling at the time of relapse identified a new internal tandem duplication mutation in FLT3 (FLT3-ITD). A bone marrow biopsy was performed, and management decisions were made.